FindTrial
Sign In

Effectiveness of non-vitamin K antagonist oral anticoagulants on renal outcomes among Thai patients with atrial fibrillation

Renal Outcome of Oral Anticoagulants among Thai patients with atrial fibrillation

Status
Unknown
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20211029003
Enrollment
80
Registered
2021-10-29
Start date
2021-11-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with non-valvular atrial fibrillation who starting oral anticoagulants therapy. Atrial fibrillation, Non-Vitamin K oral anticoagulant, Warfarin, Renal outcomes

Interventions

Patients with non-valvular atrial fibrillation or atrial flutter who starting warfarin.,Patients with non-valvular atrial fibrillation or atrial flutter who starting NOACs
Treatment,Treatment
Warfarin group,NOACs group

Sponsors

Eastern Asia University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients age 20 years or older diagnosed with non-valvular atrial fibrillation or atrial flutter, 2. Patients start on oral anticoagulants therapy for first time or up to 3 months, 3. Patients who agree to participate in this study

Exclusion criteria

Exclusion criteria: 1. Atrial fibrillation patients with moderate to severe mitral stenosis and/or mechanical valve replacement, 2. eGFR < 15 mL/min or renal replacement therapy, 3. moderate or severe hepatic disorder (equivalent to Child-Pugh classification B or C), 4. Pregnant women or breastfeeding, 5. platelet count <150,000 cell/m3, 6. Active bleeding

Design outcomes

Primary

MeasureTime frame
Change in urine albumin to creatinine ratio (UACR) at 0, 6, 12 month during study urine albumin to creatinine ratio (UACR),Change in greater than or equal to 30% decline in estimated glomerular filtration rate (eGFR) at 0, 3, 6, 9, and 12 months during study estimated glomerular filtration rate (eGFR)—

Secondary

MeasureTime frame
Change in doubling of the serum creatinine level at 0, 3, 6, 9, and 12 months during study serum creatinine level,Survival time of eGFR decline greater than or equal to 30% from baseline at 0, 3, 6, 9, and 12 months during study survival analysis,Factors associated with change in eGFR at 0, 3, 6, 9, and 12 months during study baseline characteristic from OPD card recording—

Countries

Thailand

Contacts

Public ContactKaratpetch Tongkate

Eastern Asia University

Karatpetch@eau.ac.th0623642453

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026